Intellia Therapeutics, Inc. (LON:0JBU)
11.29
-0.50 (-4.24%)
Feb 12, 2026, 5:08 PM GMT
Intellia Therapeutics Employees
Intellia Therapeutics had 403 employees as of December 31, 2024. The number of employees decreased by 123 or -23.38% compared to the previous year.
Employees
403
Change (1Y)
-123
Growth (1Y)
-23.38%
Revenue / Employee
106.20K GBP
Profits / Employee
-822.96K GBP
Market Cap
988.06M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 403 | -123 | -23.38% |
| Dec 31, 2023 | 526 | -72 | -12.04% |
| Dec 31, 2022 | 598 | 113 | 23.30% |
| Dec 31, 2021 | 485 | 173 | 55.45% |
| Dec 31, 2020 | 312 | 42 | 15.56% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,000 |
| Spire Healthcare Group | 15,703 |
| CVS Group | 8,850 |
| HUTCHMED (China) | 1,780 |
| Oxford Nanopore Technologies | 1,325 |
Intellia Therapeutics News
- 6 days ago - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 days ago - Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026 - Seeking Alpha
- 7 days ago - Notable Two Hundred Day Moving Average Cross - NTLA - Nasdaq
- 15 days ago - NTLA Stock Rating Maintained and Price Target Raised by HC Wainwright & Co. | NTLA Stock News - GuruFocus
- 16 days ago - FDA Lifts Hold on Intellia's Nexiguran Ziclumeran Program (NTLA) - GuruFocus
- 16 days ago - Intellia Moves Forward As FDA Removes Trial Hold For Rare Disorder - Benzinga
- 16 days ago - Intellia Moves Forward As FDA Removes Trial Hold For Rare Disorder - Benzinga
- 16 days ago - The Gene-Editing News That Sent Beleaguered Intellia Therapeutics Stock Up 10% - Investor's Business Daily